<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14812">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01718808</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 41/10</org_study_id>
    <nct_id>NCT01718808</nct_id>
  </id_info>
  <brief_title>Cetuximab for Elderly Patients With mCRC</brief_title>
  <official_title>Cetuximab Monotherapy and Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With KRAS- and BRAF Wild-type Metastatic Colorectal Cancer. A Multicenter Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVE: The objective of the trial is to judge on the benefit obtained by an upfront
      cetuximab treatment delivered as monotherapy or as part of a combination treatment with
      capecitabine in vulnerable elderly patients selected for V-Ki-ras2 Kirsten rat sarcoma viral
      oncogene homolog (KRAS) wild-type and B-type Raf kinase (BRAF) wild-type metastatic
      colorectal cancer (mCRC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint: If in a treatment arm the number of patients alive and without progression
      at 12 weeks is 17 or more, this arm will be considered promising, otherwise not promising.
      Additionally, a two-sided 95% confidence interval for the difference in Progression free
      survival (PFS) rates between the two arms will be calculated.

      Secondary endpoints and patient characteristics:

        -  Laboratory values may be expressed as the absolute values (continuous variables) or/and
           as grading (ordinal categorical variables).

        -  Generally for each categorical variable the results will be summarized by frequencies
           and percentages. For response rates 95% Clopper-Pearson confidence intervals will be
           calculated.

        -  For each adverse event, the results will be summarized by frequencies and percentages
           of different grades among all cycles as well as by frequencies and percentages of the
           within-patient worst grades

        -  For each continuous variable the results will be summarized by descriptive statistics.

        -  Time-to-event variables will be presented by Kaplan-Meier curves and summarized by
           medians and 95% confidence intervals.

        -  All analysis will be done by treatment arm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression free survival in week 12</measure>
    <time_frame>in week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>A progression event is defined as (whichever occurs first):
Progressive disease (PD) assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Death of any cause
Starting of second line treatment
No tumor assessment 85 days (+/- 7 days) after registration which shows stabilisation or response Patients without tumor assessment at week 12 but with a later assessment showing absence of progression without subsequent treatment will be counted as a progression free at week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life  (QL)</measure>
    <time_frame>Baseline, in week 7, 13 and 19</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (CTCAE v 4.0)</measure>
    <time_frame>Adverse events are assessed by Common terminology criteria for adverse events (CTCAE) v4.0. From randomization until 30 days after end of treatment (estimated up to 2 years).</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response (OR)</measure>
    <time_frame>Before start of treatment. In week 13 and every 12 weeks up to 2 years.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>PFS will be calculated sustained from randomization until documented PD or death, whichever occurs first (estimated up to 2 years).</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Overall survival will be calculated from randomization until death (estimated up to 2 years).</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall treatment utility (OTU) (predefined composite endpoint including clinical benefit, tolerability and acceptability of the treatment)</measure>
    <time_frame>Until week 19.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Cetuximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cetuximab 500 mg/m2 every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Cetuximab and Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cetuximab 500 mg/m2 every 2 weeks plus Capecitabine 1000 mg/m2 (*) bid d1-14 every 3 weeks
* 750 mg/m2 if creatinine-clearance 30-50 ml/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab 500 mg/m2 every second week (days 1, 15, 29, etc.) until progression or unacceptable toxicity</description>
    <arm_group_label>Arm A: Cetuximab</arm_group_label>
    <arm_group_label>Arm B: Cetuximab and Capecitabine</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000 mg/m2 bid p.o. (750 mg/m2 if creatinine clearance 30-50 ml/min according to Cockroft-Gault formula, on days 1-14 every 3 weeks, restart on day 22</description>
    <arm_group_label>Arm B: Cetuximab and Capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has given written informed consent before any trial specific treatment

          -  Histological proven diagnosis of colorectal cancer, metastatic or inoperable
             advanced, not amenable to curative therapy

          -  Measurable disease, defined as at least one lesion (outside of irradiated areas) that
             can be measured in at least one dimension as ≥ 10 mm (≥ 15 mm in case of lymph nodes)
             according to RECIST v1.1

          -  Tumour with wild-type KRAS and wild-type BRAF gene

          -  No previous systemic chemotherapy for metastatic disease (previous adjuvant
             chemotherapy is allowed if completed &gt;6 months before randomization, previous rectal
             radio-chemo therapy if completed &gt;1 month before randomization)

          -  WHO performance status 0 or 1

          -  Age &gt;75 years; or: age ≥ 70 years with at least one of the following factors:

          -  Any functional dependence as measured by Instrumental Activities of Daily Life
             (IADL). Significant comorbidity according to the Cumulative Illness Rating Scale for
             geriatric patients (CIRS-G; any severe comorbidity &gt; grade 3 or a total score &gt; 5
             qualifies)

          -  Neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L

          -  Bilirubin ≤ 2.0 x Upper Limit of Normal (ULN) (unless known Gilbert-Meulengracht
             syndrome), aspartate aminotransferase (AST)&lt;2.5xULN

          -  Calculated creatinine clearance ≥ 30 ml/min. (according to the formula of
             Cockcroft-Gault)

          -  Patient is able to swallow oral medication

          -  Baseline Quality of Life forms have been completed

        Exclusion Criteria:

          -  Documented or suspected cerebral and/or leptomeningeal metastases (no cerebral
             baseline imaging required in asymptomatic patients)

          -  Risk of rapid deterioration due to tumor symptoms or tumor complications

          -  Synchronous or prior malignancy other than adequately treated non-melanomatous skin
             cancer or in situ carcinoma of the cervix, other malignancies unless disease free &gt; 2
             years

          -  Prior anti-EGFR (Epidermal Growth Factor Receptor) antibody therapy

          -  Severe or uncontrolled cardiovascular disease (e.g. acute coronary syndromes, cardiac
             failure NYHA (New York Heart Association) III or IV, clinically relevant myopathy,
             history of myocardial infarction within the last 12 months, significant arrhythmias)

          -  Concurrent severe uncontrolled medical illness (judged by the investigator) which
             could impair the ability of the patient to participate in the trial (e.g.
             uncontrolled infection, uncontrolled diabetes mellitus, active autoimmune disease)

          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency

          -  Known hypersensitivity to trial drugs or hypersensitivity to any other component of
             the trial drug

          -  Definite contraindications for the use of corticosteroids or antihistamines as
             premedication

          -  Lack of physical integrity of the upper gastrointestinal tract or malabsorption
             syndrome or history of inflammatory intestinal disease, or other disease which could
             alter drug absorption

          -  Psychiatric disorder precluding understanding of information on trial related topics,
             giving informed consent, filling out QL forms, or interfering with compliance with
             oral drug intake

          -  Any concomitant drugs contraindicated for use with the trial drugs according to the
             Swissmedic approved product information

          -  Concurrent treatment with other experimental drugs or other anti-cancer therapy
             and/or treatment in a clinical trial within 30 days prior to randomization
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Kienle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kantonsspital Graubünden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger von Moos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kantonsspital Graubünden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ralph Winterhalder, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Luzerner Kantonsspital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dieter Köberle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scarlett Keunecke</last_name>
    <phone>+41 31 389 94 64</phone>
    <email>scarlett.keunecke@sakk.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christiane Pilop, MD</last_name>
    <phone>+41 31 389 93 49</phone>
    <email>Christiane.Pilop@sakk.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viviane Hess, MD</last_name>
      <phone>41-61-265-5714</phone>
      <email>vhess@uhbs.ch</email>
    </contact>
    <investigator>
      <last_name>Viviane Hess, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital, Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Attila Kollar, MD</last_name>
      <phone>41-031-632-41-14</phone>
      <email>attila.kollar@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Attila Kollar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Biel</name>
      <address>
        <city>Biel</city>
        <zip>CH-2501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Borner, Prof.</last_name>
      <phone>41-32-324-3714</phone>
      <email>markus.borner@szb-chb.ch</email>
    </contact>
    <investigator>
      <last_name>Markus Borner, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Fribourgeois</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Betticher, MD</last_name>
      <phone>41-26-426-7240</phone>
      <email>betticherd@h-fr.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel Betticher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud Roth, MD</last_name>
      <phone>41-22-372-7744</phone>
      <email>arnaud.roth@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Arnaud Roth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothea A. Wagner, MD</last_name>
      <phone>41-21-314-4530</phone>
      <email>Dorothea.Wagner@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Dorothea A. Wagner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Winterhalder, MD</last_name>
      <phone>+41 41 205 58 75</phone>
      <email>ralph.winterhalder@ksl.ch</email>
    </contact>
    <investigator>
      <last_name>Ralph Winterhalder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Muensterlingen</name>
      <address>
        <city>Muensterlingen</city>
        <zip>8596</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Inauen, MD</last_name>
      <phone>+41 71 686 11 11</phone>
      <email>roman.inauen@stgag.ch</email>
    </contact>
    <investigator>
      <last_name>Roman Inauen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dieter Koeberle, MD</last_name>
      <phone>41-71-494-1111</phone>
      <email>dieter.koeberle@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Dieter Köberle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SpitalSTS AG Simmental-Thun-Saanenland</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Rauch</last_name>
      <phone>+41 33 226 26 45</phone>
      <email>daniel.rauch@spitalstsag.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel Rauch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>CH-8400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabina Schacher-Kaufmann, MD</last_name>
      <phone>41-52-266-2552</phone>
      <email>sabina.schacher@ksw.ch</email>
    </contact>
    <investigator>
      <last_name>Sabina Schacher-Kaufmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik Hirslanden</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucas Widmer, MD</last_name>
      <phone>41-44-387-3780</phone>
      <email>lwidmer@onkozentrum.ch</email>
    </contact>
    <investigator>
      <last_name>Lucas Widmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Pestalozzi, MD</last_name>
      <phone>41-44-255-2214</phone>
    </contact>
    <investigator>
      <last_name>Bernhard Pestalozzi, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zürich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Schmid, Prof</last_name>
      <phone>+41 44 466 11 11</phone>
      <email>mathias.schmid@triemli.zuerich.ch</email>
    </contact>
    <investigator>
      <last_name>Mathias Schmid, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <lastchanged_date>February 7, 2014</lastchanged_date>
  <firstreceived_date>October 22, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <keyword>KRAS</keyword>
  <keyword>BRAF</keyword>
  <keyword>Wild-type Metastatic</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Phase II Trial</keyword>
  <keyword>Elderly Patients</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
